Atlas Trials

High-dose Furmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Meningeal Metastasis

Clinical trial NCT06812871 · COMPLETED

Trial details

NCT number
NCT06812871
Sponsor
Sun Yat-sen University
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer Metastatic
Start date
2024-01-01
Primary completion
2026-03-30
Enrollment
46

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.